Timothy J. Hobday, MD

Metastatic well or moderately differentiated neuroendocrine tumors of the gastrointestinal tract and lung (NETs) are a fascinating and markedly heterogeneous group of generally indolent, but relentless cancers.

Dr. Eneman and colleagues providea thorough and timely reviewof adjuvant endocrinetherapy for hormone-receptor–positiveearly breast cancer. This field is rapidlyshifting, with the accumulation of recentlypresented and published datafrom randomized trials in both pre- andpostmenopausal patients. As with mostnew clinical research data, findingsfrom these recent trials raise as manyquestions as they provide conclusions.A few of the issues discussed in thiswell-written review deserve comment.